Literature DB >> 2446641

An immunohistochemical study in thyroid cancer.

C A Beltrami1, G Barbatelli, P Criante, A Paliaga, C E Amadi.   

Abstract

Follicular, papillary, anaplastic and medullary cancers of the thyroid were investigated using immunohistochemical methods. The following antibodies were used: anti-S-100, antineuron-specific enolase (NSE), antikeratin, antithyroglobulin, anticalcitonin, anticarcinoembryonic antigen (CEA), antiepithelial membrane antigen (EMA); the following hormones were also tested in the medullary carcinoma: gastrin, ACTH and serotonin. Papillary and follicular carcinoma in particular reacted with anti-S-100 and anti-NSE; the anaplastic neoplasia reacted with anti-S-100 (25%), anti-NSE (12%), antikeratin (12%), antithyroglobulin (12%), anti-CEA (37%) and anti-EMA (37%). Medullary carcinoma reacted with anticalcitonin (100%), anti-CEA (96%), anti-NSE (79%), anti-EMA (4%) and anti-S-100 (17%). We were not able to correlate the virulence of the medullary carcinoma with the anticalcitonin and anti-CEA reactivity, while the hyperplastic C cells were immunoreactive both with calcitonin or with CEA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446641

Source DB:  PubMed          Journal:  Appl Pathol        ISSN: 0252-1172


  4 in total

Review 1.  Differential diagnosis of pheochromocytomas and paragangliomas.

Authors:  A M McNichol
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

2.  Neuroendocrine marker expression in thyroid epithelial tumors.

Authors:  F Satoh; S Umemura; M Yasuda; R Y Osamura
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 3.  Histopathology and immunohistochemistry of adrenal medullary tumors and paragangliomas.

Authors:  Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

4.  Paraganglioma of the thyroid gland: a rare entity.

Authors:  Nicolás González Poggioli; Manuel López Amado; María Teresa Yebra Pimentel
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.